Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02006485 · ClinicalTrials.gov registry record · Phase 1
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
A Phase 1 study of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma, sponsored by TG Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
- 6
- Study locations
NCT02006485: Completed Phase 1 study of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma, sponsored by TG Therapeutics.
NCT02006485 is a Phase 1 study of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma that has completed, run by TG Therapeutics. The registered enrollment target is 160 participants, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (12% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02006485, a Phase 1 study of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma, has completed, sponsored by TG Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with TGR-1202, with or without ibrutinib or bendamustine, in patients with advanced hematologic malignancies
Primary Outcome
To determine the incidence of adverse events, any potential abnormal laboratory results and any dose-limiting toxicities
Conditions Studied
Interventions
- DRUG Ublituximab + TGR-1202
- DRUG Ublituximab + TGR-1202 + ibrutinib
- DRUG Ublituximab + TGR-1202 + bendamustine
Study Locations (6)
Alabama
- TG Therapeutics Investigational Trial Site - Huntsville
Arkansas
- TG Therapeutics Investigational Trial Site - Jonesboro
California
- TG Therapeutics Investigational Trial Site - Duarte
Georgia
- TG Therapeutics Investigational Trial Site - Atlanta
Nebraska
- TG Therapeutics Investigational Trial Site - Omaha
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2013-12-13 |
| Est. Completion | 2019-10 |
| Phase | Phase 1 |
What the finished NCT02006485 record still lists
NCT02006485 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (12% lower).
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Ublituximab + TGR-1202 is the first listed.
NCT02006485 lists 6 locations in 6 states (Alabama, Arkansas, California).
Frequently Asked Questions
What is clinical trial NCT02006485 about?
NCT02006485 is a clinical study titled "Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies". The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with TGR-1202, with or without ibrutinib or bendamustine, in patients with advanced hematologic malignancies
What is the current status of trial NCT02006485?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2013-12-13. Estimated completion is 2019-10.
What conditions does trial NCT02006485 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT02006485?
The interventions under investigation include: Ublituximab + TGR-1202 (DRUG), Ublituximab + TGR-1202 + ibrutinib (DRUG), Ublituximab + TGR-1202 + bendamustine (DRUG).
Who is sponsoring clinical trial NCT02006485?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02006485 being conducted?
This trial has 6 study locations across Alabama, Arkansas, California, Georgia, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02006485's enrollment target sits among peer trials
160 48th of 187 higher than 140 of 187 other Chronic Lymphocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI